Biotech News

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx (MGTX)MeiraGTx2026-06-25 13:46 ESTCompany update

LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards to Penny Fleck in connection with

Open original release

Related news

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

View all latest news

MeiraGTx

MeiraGTx is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

MGTXMeiraGTx2026-06-26 10:02 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-06-26 10:02 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MGTXMeiraGTx2026-06-26 10:02 EST

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

MGTXMeiraGTx2026-06-26 10:02 EST

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

MGTXMeiraGTx2026-06-26 10:02 EST

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States